Home / Companies / News / Covid-19 crisis: Glenmark claims 'clinical cure in 4 days' in Phase-3 trial

Covid-19 crisis: Glenmark claims 'clinical cure in 4 days' in Phase-3 trial

Firm claims trial results showed 28.6% faster viral clearance in overall population, says drug well tolerated with no major side effects

Glenmark has completed phase-III clinical studies, with favipiravir in mild-to-moderate Covid-19 patients in India.

Premium

Glenmark plans to submit the clinical trial data for publication in a peer-reviewed journal in the coming weeks

3 min read Last Updated : Jul 23 2020 | 12:55 AM IST

Amidst controversy over the pricing and efficacy of the generic oral antiviral drug favipiravir, Glenmark Pharmaceuticals announced the top line results from a Phase 3 clinical trial of the drug in mild to moderate Covid-19 patients conducted across seven clinical sites in India.

Glenmark claimed that 69.8 per cent of patients in the favipiravir treatment arm achieved ‘clinical cure’ by Day 4, which was statistically significant, compared to 44.9 per cent observed in the control arm.

The open-label, randomised, multicentre clinical trial, conducted on 150 patients, evaluated the efficacy and safety of favipiravir plus standard supportive care (favipiravir treatment arm) versus standard

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in